Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Page 1
Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review.
Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani CD, Rashedi S, Lookstein R, Lansky A, Vedantham S, Sobieszczyk P, Mena-Hurtado C, Aghayev A, Henke P, Mehdipoor G, Tufano A, Chatterjee S, Middeldorp S, Wasan S, Bashir R, Lang IM, Shishehbor MH, Gerhard-Herman M, Giri J, Menard MT, Parikh SA, Mazzolai L, Moores L, Monreal M, Jimenez D, Goldhaber SZ, Krumholz HM, Piazza G. Bikdeli B, et al. Among authors: goldhaber sz. Semin Thromb Hemost. 2024 Jan 4. doi: 10.1055/s-0043-1777991. Online ahead of print. Semin Thromb Hemost. 2024. PMID: 38176425
Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short-term procedural risks and long-term complications, although survivors of prior procedures are occasionally encountered. ...
Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short- …
Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study.
Bikdeli B, Muriel A, Wang Y, Piazza G, Khairani CD, Rosovsky RP, Mehdipoor G, O'Donoghue ML, Madridano O, Lopez-Saez JB, Mellado M, Brasero AMD, Grandone E, Spagnolo PA, Lu Y, Bertoletti L, López-Jiménez L, Núñez MJ, Blanco-Molina Á, Gerhard-Herman M, Goldhaber SZ, Bates SM, Jimenez D, Krumholz HM, Monreal M; RIETE Investigators. Bikdeli B, et al. Among authors: goldhaber sz. Semin Thromb Hemost. 2023 Oct;49(7):725-735. doi: 10.1055/s-0043-1764231. Epub 2023 Mar 3. Semin Thromb Hemost. 2023. PMID: 36868268
Whether such differences correlate with disparities in treatment or differences in short- or long-term clinical outcomes warrants further investigation....
Whether such differences correlate with disparities in treatment or differences in short- or long-term clinical outcomes warrants fur …
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial.
Bikdeli B, Hogan H, Morrison RB, Fanikos J, Campia U, Barns BM, Pfeferman MB, Snyder JE, Khairani CD, Goldhaber SZ, Piazza G. Bikdeli B, et al. Among authors: goldhaber sz. Thromb Haemost. 2022 Jun;122(6):1061-1070. doi: 10.1055/a-1646-2244. Epub 2021 Oct 31. Thromb Haemost. 2022. PMID: 34530470 Clinical Trial.
Patients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. ...
Patients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term …
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE.
Ageno W, Farjat A, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. Ageno W, et al. Among authors: goldhaber sz. Res Pract Thromb Haemost. 2021 Feb 20;5(2):326-341. doi: 10.1002/rth2.12482. eCollection 2021 Feb. Res Pract Thromb Haemost. 2021. PMID: 33733032 Free PMC article.
INTRODUCTION: Venous thromboembolism (VTE) has a long-term risk of recurrence, dependent on the presence or absence of provoking risk factors at the time of the event. ...
INTRODUCTION: Venous thromboembolism (VTE) has a long-term risk of recurrence, dependent on the presence or absence of provoking risk …
Increasing Incidence and Declining Mortality After Cancer-Associated Venous Thromboembolism: A Nationwide Cohort Study.
Ording AG, Skjøth F, Søgaard M, Højen AA, Overvad TF, Noble S, Goldhaber SZ, Larsen TB. Ording AG, et al. Among authors: goldhaber sz. Am J Med. 2021 Jul;134(7):868-876.e5. doi: 10.1016/j.amjmed.2021.01.031. Epub 2021 Feb 22. Am J Med. 2021. PMID: 33631159
PURPOSE: The incidence of cancer-associated venous thromboembolism has increased, but whether short-term mortality after cancer-associated venous thromboembolism has changed remains uncertain. ...
PURPOSE: The incidence of cancer-associated venous thromboembolism has increased, but whether short-term mortality after cancer-assoc …
Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. O'Connell C, et al. Among authors: goldhaber sz. Oncologist. 2021 Jan;26(1):e8-e16. doi: 10.1002/onco.13584. Epub 2020 Dec 4. Oncologist. 2021. PMID: 33275319 Free PMC article. Review.
Historically, anticoagulant therapy with low-molecular-weight heparin (LMWH), given for both initial and long-term treatment, has been the preferred approach recommended by practice guidelines. ...
Historically, anticoagulant therapy with low-molecular-weight heparin (LMWH), given for both initial and long-term treatment, has bee …
One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism.
Piazza G, Sterling KM, Tapson VF, Ouriel K, Sharp ASP, Liu PY, Goldhaber SZ. Piazza G, et al. Among authors: goldhaber sz. Circ Cardiovasc Interv. 2020 Aug;13(8):e009012. doi: 10.1161/CIRCINTERVENTIONS.120.009012. Epub 2020 Aug 6. Circ Cardiovasc Interv. 2020. PMID: 32757658 Free PMC article. Clinical Trial.
BACKGROUND: Accelerated tPA (tissue-type plasminogen activator) dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis improve short-term computed tomographic-measured right ventricular (RV)-to-left ventricular diameter ratio in massive and submassive p …
BACKGROUND: Accelerated tPA (tissue-type plasminogen activator) dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis i …
Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service.
Zekery-Saad SA, Lewin A, Pham M, Sylvester KW, Fanikos J, Goldhaber SZ, Connors JM. Zekery-Saad SA, et al. Among authors: goldhaber sz. J Thromb Thrombolysis. 2021 Feb;51(2):405-412. doi: 10.1007/s11239-020-02207-3. J Thromb Thrombolysis. 2021. PMID: 32651889
Patients on long-term anticoagulation combined with antiplatelet therapy have an increased risk of bleeding compared to patients on anticoagulation alone. ...Of the 2677 patients evaluated for inclusion,145 were on concomitant long-term warfarin therapy plus aspirin …
Patients on long-term anticoagulation combined with antiplatelet therapy have an increased risk of bleeding compared to patients on a …
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation.
Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK; GARFIELD-AF Investigators. Fox KAA, et al. Among authors: goldhaber sz. JAMA Netw Open. 2020 Feb 5;3(2):e200107. doi: 10.1001/jamanetworkopen.2020.0107. JAMA Netw Open. 2020. PMID: 32101311 Free PMC article.
Patients treated with OAC plus AP also had higher rates of all clinical outcomes than those treated with OAC alone over the short term (3 months). CONCLUSIONS AND RELEVANCE: This study challenges the practice of coprescribing OAC plus AP unless there is a clear indication …
Patients treated with OAC plus AP also had higher rates of all clinical outcomes than those treated with OAC alone over the short term …
Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis.
Kahn SR, Julian JA, Kearon C, Gu CS, Cohen DJ, Magnuson EA, Comerota AJ, Goldhaber SZ, Jaff MR, Razavi MK, Kindzelski AL, Schneider JR, Kim P, Chaer R, Sista AK, McLafferty RB, Kaufman JA, Wible BC, Blinder M, Vedantham S; ATTRACT Trial Investigators. Kahn SR, et al. Among authors: goldhaber sz. J Vasc Surg Venous Lymphat Disord. 2020 Jan;8(1):8-23.e18. doi: 10.1016/j.jvsv.2019.03.023. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 31843251 Free PMC article. Clinical Trial.
We aimed to assess whether pharmacomechanical catheter-directed thrombolysis (PCDT) improves short-term or long-term QOL in patients with proximal DVT and whether QOL is related to extent of DVT. ...
We aimed to assess whether pharmacomechanical catheter-directed thrombolysis (PCDT) improves short-term or long-term QOL in pa …
60 results